Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer

NCT06696768 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06696768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06696768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
June 23, 2025
Completion date
December 31, 2026
Enrollment
24 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal adenocarcinoma, stage iii colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8, unresectable colorectal adenocarcinoma